Physician profile
Mohammed Bari
NPI 1518370600
$16,080.42
in general payments reported to CMS, 2019-2025
35 companies · $2,359 in 2025
The $2,359 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $1,714 · 2021: $1,035 · 2022: $1,515 · 2023: $3,659 · 2024: $5,461 · 2025: $2,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,065 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,294 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,064.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,293.75 |
| Education | $120.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,771.02 | 2019-2025 | Tavneos, Krystexxa, Enbrel |
| Abbvie INC. | $2,041.02 | 2019-2025 | Rinvoq, Skyrizi |
| Horizon Therapeutics Plc | $1,192.61 | 2020-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $1,107.94 | 2021-2025 | Saphnelo |
| Pfizer INC. | $1,071.51 | 2020-2025 | |
| Ucb, INC. | $873.99 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $658.31 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $596.63 | 2019-2025 | Taltz, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $462.19 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $392.26 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Mallinckrodt Hospital Products INC. | $326.70 | 2023-2025 | Acthar |
| Glaxosmithkline, LLC. | $276.02 | 2021-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $154.55 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $153.37 | 2022-2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $152.14 | 2020-2025 | Orencia, Sotyktu |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $103.87 | 2023-2025 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.30 | 2023-2024 | Cyltezo |
| Genzyme Corporation | $69.54 | 2019-2020 | |
| Radius Health, INC. | $69.35 | 2020-2022 | |
| Genentech USA, INC. | $55.55 | 2025 | Gazyva |
| Octapharma USA, INC. | $51.99 | 2023 | Octagam Immune Globulin (Human) |
| Kiniksa Pharmaceuticals, LTD. | $45.51 | 2023 | Arcalyst |
| Teva Pharmaceuticals USA, INC. | $40.65 | 2023-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $39.34 | 2021 | |
| Hospira, INC. | $38.16 | 2024-2025 | |
| Kyowa Kirin, INC. | $36.05 | 2024 | Crysvita |
| Sobi, INC | $31.99 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $30.24 | 2024 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $27.65 | 2024 | Crysvita |
| Tersera Therapeutics LLC | $24.41 | 2022 | |
| Csl Behring | $23.35 | 2025 | Hizentra |
| Teleflex LLC | $21.38 | 2023 | Urolift |
| Celgene Corporation | $20.48 | 2019 | |
| Allergan, INC. | $19.47 | 2020 | |
| Celltrion USA INC. | $18.88 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Bari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.